Norway: Idenix v. Gilead, District Court of Olso, 12-155575TVI-OTIR/01 and 13-170456TVI-OTIR/01, 21 March 2014

Both parties’ patents in dispute relate to chemical compounds that are appropriate for use in pharmaceutical drugs, in particular for the treatment of flaviviridae infections such as hepatitis C virus infections. Ruling that Idenix’ patent lacks a sufficiently clear description, and that Gilead’s patent is novel and inventive, the Oslo District Court declared Idenix’ patent invalid and handed down the judgment in favour of Gilead.

A full summary of this case has been published on Kluwer IP Law.